Paolo Antonio Ascierto (P A Ascierto, Paolo Ascierto, Paolo A Ascierto)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 179

Top Venues

Journal for immunotherapy of cancer

Journal of translational medicine

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Cancers

This page only lists publications with an associated author ORCID identifier.

Publications

Dirk Schadendorf, Jason John Luke, Paolo Antonio Ascierto, Georgina V Long, Piotr Lukasz Rutkowski, Adnan Khattak, Michele Del Vecchio, Luis de la Cruz Merino, Jacek Mackiewicz, Vanna Chiarion Sileni, John M Kirkwood, Caroline Robert, Jean-Jacques Grob, Reinhard Dummer, Matteo S Carlino, Yujie Zhao, Mizuho Kalabis, Clemens Krepler, Alexander Eggermont, Richard A Scolyer
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. Journal for immunotherapy of cancer 12 (3) (2024)
Jeffrey S Weber, Michele Del Vecchio, Mario Mandala, Helen J Gogas, Ana M Arance, Stephane Dalle, C Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion Sileni, Ivan Marquez-Rodas, Marcus O Butler, Anna Maria Di Giacomo, Luis de la Cruz Merino, Petr Arenberger, Victoria Atkinson, Andrew Hill, Leslie A Fecher, Michael Millward, Nikhil I Khushalani, Paola Queirolo, Georgina V Long, Maurice Lobo, Margarita Askelson, Paolo Antonio Ascierto, James M G Larkin
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Paolo Antonio Ascierto, Milena Casula, Jenny Bulgarelli, Marina Pisano, Claudia Piccinini, Luisa Piccin, Antonio Cossu, Mario Mandala, Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Lukasz Rutkowski, Virginia Ferraresi, Ana M Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbè, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F Sanmamed, Domenico Mallardo, Miriam Paone, Maria Grazia Vitale, Ignacio Melero Bermejo, Antonio M Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion Sileni, Giuseppe Palmieri
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. Nature communications 15 (1) (2024)
Paolo Antonio Ascierto, Milena Casula, Jenny Bulgarelli, Marina Pisano, Claudia Piccinini, Luisa Piccin, Antonio Cossu, Mario Mandala, Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Lukasz Rutkowski, Virginia Ferraresi, Ana M Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbè, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F Sanmamed, Domenico Mallardo, Miriam Paone, Maria Grazia Vitale, Ignacio Melero Bermejo, Antonio M Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion Sileni, Giuseppe Palmieri
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. Nature communications 15 (1) (2024)
Jason John Luke, Paolo Antonio Ascierto, Muhammad A Khattak, Luis de la Cruz Merino, Michele Del Vecchio, Piotr Lukasz Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion Sileni, Joanne M Jeter, Caroline Robert, Jean-Jacques Grob, Federica de Galitiis, Dirk Schadendorf, Matteo S Carlino, Xi Lawrence Wu, Mizuho Kalabis, Clemens Krepler, Alexander M M Eggermont, Georgina V Long
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (14) (2024)
Jedd D Wolchok, Vanna Chiarion-Sileni, Piotr Rutkowski, C Lance Cowey, Dirk Schadendorf, John Wagstaff, Paola Queirolo, Reinhard Dummer, Marcus O Butler, Andrew G Hill, Michael A Postow, Caroline Gaudy-Marqueste, Theresa Medina, Christopher D Lao, John Walker, Iván Márquez-Rodas, John B A G Haanen, Massimo Guidoboni, Michele Maio, Patrick Schöffski, Matteo S Carlino, Shahneen Sandhu, Céleste Lebbé, Paolo Antonio Ascierto, Georgina V Long, Corey Ritchings, Ayman Nassar, Margarita Askelson, Melanie Pe Benito, Wenjia Wang, F Stephen Hodi, James Larkin, null null
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. The New England journal of medicine (2024)
Michael Schenker, Mauricio Burotto, Martin Richardet, Tudor-Eliade Ciuleanu, Anthony Gonçalves, Neeltje Steeghs, Patrick Schoffski, Paolo Antonio Ascierto, Michele Maio, Iwona Lugowska, Lorena Lupinacci, Alexandra Leary, Jean-Pierre Delord, Julieta Grasselli, David S P Tan, Jennifer Friedmann, Jacqueline Vuky, Marina Tschaika, Somasekhar Konduru, Sai Vikram Vemula, Ruta Slepetis, Georgia Kollia, Misena Pacius, Quyen Duong, Ning Huang, Parul Doshi, Jonathan Baden, Massimo Di Nicola
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. Journal for immunotherapy of cancer 12 (8) (2024)
Joanne M Jeter, Michele Del Vecchio, Jeffrey Weber, Christoph Hoeller, Jean-Jacques Grob, Peter Mohr, Carmen Loquai, Caroline Dutriaux, Vanna Chiarion-Sileni, Jacek Mackiewicz, Piotr Rutkowski, Petr Arenberger, Gaelle Quereux, Tarek M Meniawy, Paolo Antonio Ascierto, Alexander M Menzies, Piyush Durani, Maurice Lobo, Federico Campigotto, Brian Gastman, Georgina V Long
Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nature medicine (2024)
Christian U Blank, Minke W Lucas, Richard A Scolyer, Bart A van de Wiel, Alexander M Menzies, Marta Lopez-Yurda, Lotte L Hoeijmakers, Robyn P M Saw, Judith M Lijnsvelt, Nigel G Maher, Saskia M Pulleman, Maria Gonzalez, Alejandro Torres Acosta, Winan J van Houdt, Serigne N Lo, Anke M J Kuijpers, Andrew Spillane, W Martin C Klop, Thomas E Pennington, Charlotte L Zuur, Kerwin F Shannon, Beatrijs A Seinstra, Robert V Rawson, John B A G Haanen, Sydney Ch'ng, Kishan A T Naipal, Jonathan Stretch, Johannes V van Thienen, Michael A Rtshiladze, Sofie Wilgenhof, Rony Kapoor, Aafke Meerveld-Eggink, Lindsay G Grijpink-Ongering, Alexander C J van Akkooi, Irene L M Reijers, David E Gyorki, Dirk J Grünhagen, Frank M Speetjens, Sonja B Vliek, Joanna Placzke, Lavinia Spain, Robert C Stassen, Mona Amini-Adle, Céleste Lebbé, Mark B Faries, Caroline Robert, Paolo Antonio Ascierto, Rozemarijn van Rijn, Franchette W P J van den Berkmortel, Djura Piersma, Andre van der Westhuizen, Gerard Vreugdenhil, Maureen J B Aarts, Marion A M Stevense-den Boer, Victoria Atkinson, Muhammad Khattak, Miles C Andrews, Alfons J M van den Eertwegh, Marye J Boers-Sonderen, Geke A P Hospers, Matteo S Carlino, Jan-Willem B de Groot, Ellen Kapiteijn, Karijn P M Suijkerbuijk, Piotr Rutkowski, Shahneen Sandhu, Astrid A M van der Veldt, Georgina V Long
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. The New England journal of medicine (2024)
Jason John Luke, Paolo Antonio Ascierto, Muhammad A Khattak, Luis de la Cruz Merino, Michele Del Vecchio, Piotr Lukasz Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion Sileni, Joanne M Jeter, Caroline Robert, Jean-Jacques Grob, Federica de Galitiis, Dirk Schadendorf, Matteo S Carlino, Xi Lawrence Wu, Mizuho Kalabis, Clemens Krepler, Alexander M M Eggermont, Georgina V Long
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (14) (2024)
Jason John Luke, Omid Hamid, Bernard A Fox, Paolo Antonio Ascierto, Iman Osman, James J Mule, Pedro J Romero, Michael T Lotze
Jeffrey S Weber, MD, PhD (1952-2024): in memoriam to discovery, friendship and family. Journal for immunotherapy of cancer 12 (9) (2024)
Hannah Burnette, Aliyah Pabani, Mitchell S von Itzstein, Benjamin Switzer, Run Fan, Fei Ye, Igor Puzanov, Jarushka Naidoo, Paolo Antonio Ascierto, David E Gerber, Marc S Ernstoff, Douglas B Johnson
Use of artificial intelligence chatbots in clinical management of immune-related adverse events. Journal for immunotherapy of cancer 12 (5) (2024)
Marialuisa Trocchia, Annagioia Ventrici, Luca Modestino, Leonardo Cristinziano, Anne Lise Ferrara, Francesco Palestra, Stefania Loffredo, Mariaelena Capone, Gabriele Madonna, Marilena Romanelli, Paolo Antonio Ascierto, Maria Rosaria Galdiero
Innate Immune Cells in Melanoma: Implications for Immunotherapy. International journal of molecular sciences 25 (15) (2024)
Domenico Liguoro, Rachele Frigerio, Arianna Ortolano, Andrea Sacconi, Mario Acunzo, Giulia Romano, Giovanni Nigita, Barbara Bellei, Gabriele Madonna, Mariaelena Capone, Paolo Antonio Ascierto, Rita Mancini, Gennaro Ciliberto, Luigi Fattore
The MITF/mir-579-3p regulatory axis dictates BRAF-mutated melanoma cell fate in response to MAPK inhibitors. Cell death & disease 15 (3) (2024)
Georgina V Long, Evan J Lipson, F Stephen Hodi, Paolo Antonio Ascierto, James M G Larkin, Christopher Lao, Jean-Jacques Grob, Flavia Ejzykowicz, Andriy Moshyk, Viviana Garcia-Horton, Zheng-Yi Zhou, Yiqiao Xin, Jennell Palaia, Laura McDonald, Sarah Keidel, Anthony Salvatore, Divya Patel, Leon A Sakkal, Hussein A Tawbi, Dirk Schadendorf
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Dirk Schadendorf, Jason John Luke, Paolo Antonio Ascierto, Georgina V Long, Piotr Lukasz Rutkowski, Adnan Khattak, Michele Del Vecchio, Luis de la Cruz Merino, Jacek Mackiewicz, Vanna Chiarion Sileni, John M Kirkwood, Caroline Robert, Jean-Jacques Grob, Reinhard Dummer, Matteo S Carlino, Yujie Zhao, Mizuho Kalabis, Clemens Krepler, Alexander Eggermont, Richard A Scolyer
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. Journal for immunotherapy of cancer 12 (3) (2024)
Hannah Burnette, Aliyah Pabani, Mitchell S von Itzstein, Benjamin Switzer, Run Fan, Fei Ye, Igor Puzanov, Jarushka Naidoo, Paolo Antonio Ascierto, David E Gerber, Marc S Ernstoff, Douglas B Johnson
Use of artificial intelligence chatbots in clinical management of immune-related adverse events. Journal for immunotherapy of cancer 12 (5) (2024)
Jason John Luke, Paolo Antonio Ascierto, Muhammad A Khattak, Luis de la Cruz Merino, Michele Del Vecchio, Piotr Lukasz Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion Sileni, Joanne M Jeter, Caroline Robert, Jean-Jacques Grob, Federica de Galitiis, Dirk Schadendorf, Matteo S Carlino, Xi Lawrence Wu, Mizuho Kalabis, Clemens Krepler, Alexander M M Eggermont, Georgina V Long
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (14) (2024)
Marialuisa Trocchia, Annagioia Ventrici, Luca Modestino, Leonardo Cristinziano, Anne Lise Ferrara, Francesco Palestra, Stefania Loffredo, Mariaelena Capone, Gabriele Madonna, Marilena Romanelli, Paolo Antonio Ascierto, Maria Rosaria Galdiero
Innate Immune Cells in Melanoma: Implications for Immunotherapy. International journal of molecular sciences 25 (15) (2024)
Dirk Schadendorf, Jason John Luke, Paolo Antonio Ascierto, Georgina V Long, Piotr Lukasz Rutkowski, Adnan Khattak, Michele Del Vecchio, Luis de la Cruz Merino, Jacek Mackiewicz, Vanna Chiarion Sileni, John M Kirkwood, Caroline Robert, Jean-Jacques Grob, Reinhard Dummer, Matteo S Carlino, Yujie Zhao, Mizuho Kalabis, Clemens Krepler, Alexander Eggermont, Richard A Scolyer
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. Journal for immunotherapy of cancer 12 (3) (2024)
Domenico Liguoro, Rachele Frigerio, Arianna Ortolano, Andrea Sacconi, Mario Acunzo, Giulia Romano, Giovanni Nigita, Barbara Bellei, Gabriele Madonna, Mariaelena Capone, Paolo Antonio Ascierto, Rita Mancini, Gennaro Ciliberto, Luigi Fattore
The MITF/mir-579-3p regulatory axis dictates BRAF-mutated melanoma cell fate in response to MAPK inhibitors. Cell death & disease 15 (3) (2024)
Domenico Liguoro, Rachele Frigerio, Arianna Ortolano, Andrea Sacconi, Mario Acunzo, Giulia Romano, Giovanni Nigita, Barbara Bellei, Gabriele Madonna, Mariaelena Capone, Paolo Antonio Ascierto, Rita Mancini, Gennaro Ciliberto, Luigi Fattore
The MITF/mir-579-3p regulatory axis dictates BRAF-mutated melanoma cell fate in response to MAPK inhibitors. Cell death & disease 15 (3) (2024)
Dirk Schadendorf, Jason John Luke, Paolo Antonio Ascierto, Georgina V Long, Piotr Lukasz Rutkowski, Adnan Khattak, Michele Del Vecchio, Luis de la Cruz Merino, Jacek Mackiewicz, Vanna Chiarion Sileni, John M Kirkwood, Caroline Robert, Jean-Jacques Grob, Reinhard Dummer, Matteo S Carlino, Yujie Zhao, Mizuho Kalabis, Clemens Krepler, Alexander Eggermont, Richard A Scolyer
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. Journal for immunotherapy of cancer 12 (3) (2024)
Jason John Luke, Paolo Antonio Ascierto, Muhammad A Khattak, Luis de la Cruz Merino, Michele Del Vecchio, Piotr Lukasz Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion Sileni, Joanne M Jeter, Caroline Robert, Jean-Jacques Grob, Federica de Galitiis, Dirk Schadendorf, Matteo S Carlino, Xi Lawrence Wu, Mizuho Kalabis, Clemens Krepler, Alexander M M Eggermont, Georgina V Long
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Dirk Schadendorf, Jason John Luke, Paolo Antonio Ascierto, Georgina V Long, Piotr Lukasz Rutkowski, Adnan Khattak, Michele Del Vecchio, Luis de la Cruz Merino, Jacek Mackiewicz, Vanna Chiarion Sileni, John M Kirkwood, Caroline Robert, Jean-Jacques Grob, Reinhard Dummer, Matteo S Carlino, Yujie Zhao, Mizuho Kalabis, Clemens Krepler, Alexander Eggermont, Richard A Scolyer
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. Journal for immunotherapy of cancer 12 (3) (2024)
Domenico Galati, Domenico Mallardo, Carmine Nicastro, Serena Zanotta, Ludovica Capitelli, Carmen Lombardi, Bianca Baino, Ernesta Cavalcanti, Silvia Sale, Francesco Labonia, Rita Boenzi, Luigi Atripaldi, Paolo Antonio Ascierto, Marialuisa Bocchino
The Dysregulation of the Monocyte-Dendritic Cell Interplay Is Associated with In-Hospital Mortality in COVID-19 Pneumonia. Journal of clinical medicine 13 (9) (2024)
Hannah Burnette, Aliyah Pabani, Mitchell S von Itzstein, Benjamin Switzer, Run Fan, Fei Ye, Igor Puzanov, Jarushka Naidoo, Paolo Antonio Ascierto, David E Gerber, Marc S Ernstoff, Douglas B Johnson
Use of artificial intelligence chatbots in clinical management of immune-related adverse events. Journal for immunotherapy of cancer 12 (5) (2024)
Domenico Galati, Domenico Mallardo, Carmine Nicastro, Serena Zanotta, Ludovica Capitelli, Carmen Lombardi, Bianca Baino, Ernesta Cavalcanti, Silvia Sale, Francesco Labonia, Rita Boenzi, Luigi Atripaldi, Paolo Antonio Ascierto, Marialuisa Bocchino
The Dysregulation of the Monocyte-Dendritic Cell Interplay Is Associated with In-Hospital Mortality in COVID-19 Pneumonia. Journal of clinical medicine 13 (9) (2024)
Jason John Luke, Paolo Antonio Ascierto, Muhammad A Khattak, Luis de la Cruz Merino, Michele Del Vecchio, Piotr Lukasz Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion Sileni, Joanne M Jeter, Caroline Robert, Jean-Jacques Grob, Federica de Galitiis, Dirk Schadendorf, Matteo S Carlino, Xi Lawrence Wu, Mizuho Kalabis, Clemens Krepler, Alexander M M Eggermont, Georgina V Long
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (14) (2024)
Michael Schenker, Mauricio Burotto, Martin Richardet, Tudor-Eliade Ciuleanu, Anthony Gonçalves, Neeltje Steeghs, Patrick Schoffski, Paolo Antonio Ascierto, Michele Maio, Iwona Lugowska, Lorena Lupinacci, Alexandra Leary, Jean-Pierre Delord, Julieta Grasselli, David S P Tan, Jennifer Friedmann, Jacqueline Vuky, Marina Tschaika, Somasekhar Konduru, Sai Vikram Vemula, Ruta Slepetis, Georgia Kollia, Misena Pacius, Quyen Duong, Ning Huang, Parul Doshi, Jonathan Baden, Massimo Di Nicola
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. Journal for immunotherapy of cancer 12 (8) (2024)
Michael Schenker, Mauricio Burotto, Martin Richardet, Tudor-Eliade Ciuleanu, Anthony Gonçalves, Neeltje Steeghs, Patrick Schoffski, Paolo Antonio Ascierto, Michele Maio, Iwona Lugowska, Lorena Lupinacci, Alexandra Leary, Jean-Pierre Delord, Julieta Grasselli, David S P Tan, Jennifer Friedmann, Jacqueline Vuky, Marina Tschaika, Somasekhar Konduru, Sai Vikram Vemula, Ruta Slepetis, Georgia Kollia, Misena Pacius, Quyen Duong, Ning Huang, Parul Doshi, Jonathan Baden, Massimo Di Nicola
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. Journal for immunotherapy of cancer 12 (8) (2024)
Susan Costantini, Gabriele Madonna, Elena Di Gennaro, Francesca Capone, Palmina Bagnara, Mariaelena Capone, Silvia Sale, Carmine Nicastro, Lidia Atripaldi, Giuseppe Fiorentino, Roberto Parrella, Vincenzo Montesarchio, Luigi Atripaldi, Paolo Antonio Ascierto, Alfredo Budillon
New Insights into the Identification of Metabolites and Cytokines Predictive of Outcome for Patients with Severe SARS-CoV-2 Infection Showed Similarity with Cancer. International journal of molecular sciences 24 (5) (2023)
Domenico Mallardo, Rachel Woodford, Alexander M Menzies, Lisa Zimmer, Andrew Williamson, Egle Ramelyte, Florentia Dimitriou, Alexandre Wicky, Roslyn Wallace, Mario Mallardo, Alessio Cortellini, Alfredo Budillon, Victoria Atkinson, Shahneen Sandhu, Michielin Olivier, Reinhard Dummer, Paul Lorigan, Dirk Schadendorf, Georgina V Long, Ester Simeone, Paolo Antonio Ascierto
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab. Journal of translational medicine 21 (1) (2023)
Paolo Antonio Ascierto, Renier Brentjens, Samir N Khleif, Kunle Odunsi, Katayoun Rezvani, Marco Ruella, Ryan J Sullivan, Bernard A Fox, Igor Puzanov
The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022. Journal of translational medicine 21 (1) (2023)
Paolo Antonio Ascierto, Christian Blank, Alexander M Eggermont, Claus Garbe, Jeffrey E Gershenwald, Omid Hamid, Axel Hauschild, Jason J Luke, Janice M Mehnert, Jeffrey A Sosman, Hussein A Tawbi, Mario Mandalà, Alessandro Testori, Corrado Caracò, Iman Osman, Igor Puzanov
The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022. Journal of translational medicine 21 (1) (2023)
Domenico Mallardo, Ester Simeone, Lucia Festino, Marilena Tuffanelli, Vito Vanella, Claudia Trojaniello, Maria Grazia Vitale, Margaret Ottaviano, Mariaelena Capone, Gabriele Madonna, Francesca Sparano, Eleonora Cioli, Luigi Scarpato, Marco Palla, Rossella Di Trolio, Paolo Meinardi, Corrado Caracò, Gerardo Ferrara, Paolo Muto, Ernesta Cavalcanti, Paolo Antonio Ascierto
IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab. Journal of translational medicine 21 (1) (2023)
Paolo Antonio Ascierto, Renier Brentjens, Samir N Khleif, Kunle Odunsi, Katayoun Rezvani, Marco Ruella, Ryan J Sullivan, Bernard A Fox, Igor Puzanov
The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022. Journal of translational medicine 21 (1) (2023)
Paolo Antonio Ascierto, Renier Brentjens, Samir N Khleif, Kunle Odunsi, Katayoun Rezvani, Marco Ruella, Ryan J Sullivan, Bernard A Fox, Igor Puzanov
The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022. Journal of translational medicine 21 (1) (2023)
Adi Diab, Helen J Gogas, Shahneen Sandhu, Georgina V Long, Paolo Antonio Ascierto, James M G Larkin, Mario Sznol, Fabio Franke, Tudor E Ciuleanu, Caio Pereira, Eva Muñoz Couselo, Fernanda Bronzon Damian, Michael Schenker, Aldo Perfetti, Celeste Lebbè, Gaëlle Quéreux, Friedegund Meier, Brendan D Curti, Carlos Rojas, Yull Arriaga, Haisu Yang, Ming Zhou, Shruthi Ravimohan, Paul Statkevich, Mary A Tagliaferri, Nikhil I Khushalani
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Vincenza Granata, Roberta Fusco, Sergio Venanzio Setola, Igino Simonetti, Carmine Picone, Ester Simeone, Lucia Festino, Vito Vanella, Maria Grazia Vitale, Agnese Montanino, Alessandro Morabito, Francesco Izzo, Paolo Antonio Ascierto, Antonella Petrillo
Immunotherapy Assessment: A New Paradigm for Radiologists. Diagnostics (Basel, Switzerland) 13 (2) (2023)
Vincenza Granata, Roberta Fusco, Sergio Venanzio Setola, Igino Simonetti, Carmine Picone, Ester Simeone, Lucia Festino, Vito Vanella, Maria Grazia Vitale, Agnese Montanino, Alessandro Morabito, Francesco Izzo, Paolo Antonio Ascierto, Antonella Petrillo
Immunotherapy Assessment: A New Paradigm for Radiologists. Diagnostics (Basel, Switzerland) 13 (2) (2023)
Paolo Antonio Ascierto, Renier Brentjens, Samir N Khleif, Kunle Odunsi, Katayoun Rezvani, Marco Ruella, Ryan J Sullivan, Bernard A Fox, Igor Puzanov
The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022. Journal of translational medicine 21 (1) (2023)
Luca Giovanni Campana, Sofia Farronato, Jackie Hodgetts, Joy Odili, Antonella Vecchiato, Alison Bracken, Susanne Baier, Falk G Bechara, Lorenzo Borgognoni, Corrado Caracò, Sara Carvalhal, Piero Covarelli, James Clover, Klaus Eisendle, Fabrizio Fantini, Maria Teresa Fierro, Victor Farricha, Chiara Gregorelli, Jürg Hafner, Christian Kunte, Gianni Gerlini, Schapoor Hessam, Mario Mandalà, Dario Piazzalunga, Pietro Quaglino, Marko Snoj, Alastair Mackenzie Ross, Béatrice Trigona, David Moreno-Ramirez, Francesca Tauceri, Howard Peach, Piotr Rutkowski, Tobian Muir, Francesca de Terlizzi, Roberto Patuzzo, Michael Mühlstädt, Karin-Almut Dietrich, Thomas Mussack, Paolo Matteucci, Erika Gabriella Kis, Paolo Antonio Ascierto, Gregor Sersa, Sara Valpione, null null
European e-Delphi process to define expert consensus on electrochemotherapy treatment indications, procedural aspects, and quality indicators in melanoma. The British journal of surgery (2023)
Domenico Galati, Serena Zanotta, Mariaelena Capone, Gabriele Madonna, Domenico Mallardo, Marilena Romanelli, Ester Simeone, Lucia Festino, Francesca Sparano, Rosa Azzaro, Rosaria De Filippi, Antonello Pinto, Chrystal M Paulos, Paolo Antonio Ascierto
Potential clinical implications of CD4 + CD26 high T cells for nivolumab treated melanoma patients. Journal of translational medicine 21 (1) (2023)
Paolo Antonio Ascierto, Antonio Avallone, Carlo Bifulco, Sergio Bracarda, Joshua D Brody, Leisha A Emens, Robert L Ferris, Silvia C Formenti, Omid Hamid, Douglas B Johnson, Tomas Kirchhoff, Christopher A Klebanoff, Gregory B Lesinski, Anne Monette, Bart Neyns, Kunle Odunsi, Chrystal M Paulos, Daniel J Powell, Katayoun Rezvani, Brahm H Segal, Nathan Singh, Ryan J Sullivan, Bernard A Fox, Igor Puzanov
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022). Journal of translational medicine 21 (1) (2023)
Paolo Antonio Ascierto, Reinhard Dummer, Helen J Gogas, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer, Vanna Chiarion Sileni, Caroline Dutriaux, Jan Willem B de Groot, Naoya Yamazaki, Carmen Loquai, Caroline Robert, Keith T Flaherty
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF -Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Domenico Galati, Serena Zanotta, Mariaelena Capone, Gabriele Madonna, Domenico Mallardo, Marilena Romanelli, Ester Simeone, Lucia Festino, Francesca Sparano, Rosa Azzaro, Rosaria De Filippi, Antonello Pinto, Chrystal M Paulos, Paolo Antonio Ascierto
Potential clinical implications of CD4 + CD26 high T cells for nivolumab treated melanoma patients. Journal of translational medicine 21 (1) (2023)
Michael B Atkins, Paolo Antonio Ascierto, David Feltquate, James L Gulley, Douglas B Johnson, Nikhil I Khushalani, Jeffrey Sosman, Timonthy A Yap, Harriet M Kluger, Ryan J Sullivan, Hussein A Tawbi
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies. Journal for immunotherapy of cancer 11 (3) (2023)
Paolo Antonio Ascierto, Evan J Lipson, Reinhard Dummer, James M G Larkin, Georgina V Long, Rachel E Sanborn, Vanna Chiarion Sileni, Brigitte Dreno, Stéphane Dalle, Dirk Schadendorf, Margaret K Callahan, Marta Nyakas, Victoria Atkinson, Carlos Alberto Gomez Roca, Naoya Yamazaki, Hussein A Tawbi, Naomey Sarkis, Deepti M Warad, Sonia Dolfi, Priyam Mitra, Satyendra Suryawanshi, Jean-Jacques Grob
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Paolo Antonio Ascierto, Renier Brentjens, Samir N Khleif, Kunle Odunsi, Katayoun Rezvani, Marco Ruella, Ryan J Sullivan, Bernard A Fox, Igor Puzanov
The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022. Journal of translational medicine 21 (1) (2023)
Domenico Galati, Serena Zanotta, Mariaelena Capone, Gabriele Madonna, Domenico Mallardo, Marilena Romanelli, Ester Simeone, Lucia Festino, Francesca Sparano, Rosa Azzaro, Rosaria De Filippi, Antonello Pinto, Chrystal M Paulos, Paolo Antonio Ascierto
Potential clinical implications of CD4 + CD26 high T cells for nivolumab treated melanoma patients. Journal of translational medicine 21 (1) (2023)
Alessio Cortellini, Antonio D'Alessio, Siobhan Cleary, Sebastiano Buti, Melissa Bersanelli, Paola Bordi, Giuseppe Tonini, Bruno Vincenzi, Marco Tucci, Alessandro Russo, Francesco Pantano, Marco Russano, Luigia Stefania Stucci, Maria Chiara Sergi, Martina Falconi, Maria Antonietta Zarzana, Daniele Santini, Francesco Spagnolo, Enrica Teresa Tanda, Francesca Rastelli, Francesca Chiara Giorgi, Federica Pergolesi, Raffaele Giusti, Marco Filetti, Francesca Lo Bianco, Marina Chiara Garassino, Andrea Botticelli, Alain J Gelibter, Marco Siringo, Marco Ferrari, Riccardo Marconcini, Maria Giuseppa Vitale, Linda Nicolardi, Rita Chiari, Michele Ghidini, Olga Nigro, Francesco Grossi, Michele De Tursi, Pietro Di Marino, Paola Queirolo, Sergio Bracarda, Serena Macrini, Alessandro Inno, Federica Zoratto, Enzo Veltri, Chiara Spoto, Maria Grazia Vitale, Katia Cannita, Alessandra Gennari, Daniel Laurence Morganstein, Domenico Mallardo, Lorenzo Nibid, Giovanna Sabarese, Leonardo Brunetti, Giuseppe Perrone, Paolo Antonio Ascierto, Corrado Ficorella, David James Pinato
Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Joanne M Jeter, Michele Del Vecchio, Jeffrey Weber, Christoph Hoeller, Jean-Jacques Grob, Peter Mohr, Carmen Loquai, Caroline Dutriaux, Vanna Chiarion-Sileni, Jacek Mackiewicz, Piotr Rutkowski, Petr Arenberger, Gaelle Quereux, Tarek M Meniawy, Paolo Antonio Ascierto, Alexander M Menzies, Piyush Durani, Maurice Lobo, Federico Campigotto, Brian Gastman, Georgina V Long
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nature medicine (2023)
Domenico Mallardo, Ester Simeone, Lucia Festino, Marilena Tuffanelli, Vito Vanella, Claudia Trojaniello, Maria Grazia Vitale, Margaret Ottaviano, Mariaelena Capone, Gabriele Madonna, Francesca Sparano, Eleonora Cioli, Luigi Scarpato, Marco Palla, Rossella Di Trolio, Paolo Meinardi, Corrado Caracò, Gerardo Ferrara, Paolo Muto, Ernesta Cavalcanti, Paolo Antonio Ascierto
IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab. Journal of translational medicine 21 (1) (2023)
Domenico Galati, Serena Zanotta, Mariaelena Capone, Gabriele Madonna, Domenico Mallardo, Marilena Romanelli, Ester Simeone, Lucia Festino, Francesca Sparano, Rosa Azzaro, Rosaria De Filippi, Antonello Pinto, Chrystal M Paulos, Paolo Antonio Ascierto
Potential clinical implications of CD4 + CD26 high T cells for nivolumab treated melanoma patients. Journal of translational medicine 21 (1) (2023)
Paolo Antonio Ascierto, Sanjiv S Agarwala, Allison Betof Warner, Marc S Ernstoff, Bernard A Fox, Thomas F Gajewski, Jérôme Galon, Claus Garbe, Brian R Gastman, Jeffrey E Gershenwald, Pawel Kalinski, Michelle Krogsgaard, Rom S Leidner, Roger S Lo, Alexander M Menzies, Olivier Michielin, Poulikos I Poulikakos, Jeffrey S Weber, Corrado Caracò, Iman Osman, Igor Puzanov, Magdalena Thurin
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy). Journal of translational medicine 21 (1) (2023)
Vincenza Granata, Roberta Fusco, Sergio Venanzio Setola, Igino Simonetti, Carmine Picone, Ester Simeone, Lucia Festino, Vito Vanella, Maria Grazia Vitale, Agnese Montanino, Alessandro Morabito, Francesco Izzo, Paolo Antonio Ascierto, Antonella Petrillo
Immunotherapy Assessment: A New Paradigm for Radiologists. Diagnostics (Basel, Switzerland) 13 (2) (2023)
Filippo de Braud, Christophe Dooms, Rebecca S Heist, Celeste Lebbè, Martin Wermke, Anas Gazzah, Dirk Schadendorf, Piotr Lukasz Rutkowski, Juergen Wolf, Paolo Antonio Ascierto, Ignacio Gil-Bazo, Shumei Kato, Maria Wolodarski, Meredith A McKean, Eva Muñoz Couselo, Martin Sebastian, Armando Santoro, Vesselina Cooke, Luca Manganelli, Kitty Wan, Anil Gaur, Jaeyeon Kim, Giordano Caponigro, Xuân-Mai Couillebault, Helen Evans, Catarina D Campbell, Sumit Basu, Michele Moschetta, Adil I Daud
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS -Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Paolo Antonio Ascierto, Renier Brentjens, Samir N Khleif, Kunle Odunsi, Katayoun Rezvani, Marco Ruella, Ryan J Sullivan, Bernard A Fox, Igor Puzanov
The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022. Journal of translational medicine 21 (1) (2023)
Domenico Mallardo, Ester Simeone, Lucia Festino, Marilena Tuffanelli, Vito Vanella, Claudia Trojaniello, Maria Grazia Vitale, Margaret Ottaviano, Mariaelena Capone, Gabriele Madonna, Francesca Sparano, Eleonora Cioli, Luigi Scarpato, Marco Palla, Rossella Di Trolio, Paolo Meinardi, Corrado Caracò, Gerardo Ferrara, Paolo Muto, Ernesta Cavalcanti, Paolo Antonio Ascierto
IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab. Journal of translational medicine 21 (1) (2023)
Rahul Seth, Sanjiv S Agarwala, Hans Messersmith, Krishna C Alluri, Paolo Antonio Ascierto, Michael B Atkins, Kathryn Bollin, Matías Chacón, Nancy B Davis, Mark B Faries, Pauline Funchain, Jason S Gold, Samantha Guild, David E Gyorki, Varinder Kaur, Nikhil I Khushalani, Joanne M Jeter, Jennifer Leigh McQuade, Michael O Meyers, Anthony Provenzano, Caroline Robert, Mario Santinami, Amikar Sehdev, Vernon K Sondak, Gilliosa Spurrier, Umang Swami, Thach-Giao Truong, Katy K Tsai, Alexander C J van Akkooi, Jeffrey S Weber
Systemic Therapy for Melanoma: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Michael B Atkins, Paolo Antonio Ascierto, David Feltquate, James L Gulley, Douglas B Johnson, Nikhil I Khushalani, Jeffrey Sosman, Timonthy A Yap, Harriet M Kluger, Ryan J Sullivan, Hussein A Tawbi
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies. Journal for immunotherapy of cancer 11 (3) (2023)
Claus Garbe, Reinhard Dummer, Teresa Amaral, Rodabe N Amaria, Paolo Antonio Ascierto, Elizabeth M Burton, Brigitte Dreno, Alexander M M Eggermont, Axel Hauschild, Christoph Hoeller, Roland Kaufmann, Celeste Lebbè, Mario Mandala, Alexander M Menzies, David Moreno, Olivier Michielin, Paul Nathan, Sapna Pradyuman Patel, Caroline Robert, Dirk Schadendorf, Paul C Lorigan, Richard A Scolyer, Hussein A Tawbi, Bart A van de Wiel, Christian U Blank, Georgina V Long
Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. Nature medicine (2023)
Omid Hamid, Jessica C Hassel, Alexander N Shoushtari, Friedegund Meier, Todd M Bauer, April K S Salama, John M Kirkwood, Paolo Antonio Ascierto, Paul C Lorigan, Cornelia Mauch, Marlana Orloff, Thomas R Jeffry Evans, Chris Holland, Ramakrishna Edukulla, Shaad E Abedin, Mark Ross Middleton
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study. Journal for immunotherapy of cancer 11 (6) (2023)
Paolo Antonio Ascierto, Renier Brentjens, Samir N Khleif, Kunle Odunsi, Katayoun Rezvani, Marco Ruella, Ryan J Sullivan, Bernard A Fox, Igor Puzanov
The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022. Journal of translational medicine 21 (1) (2023)
Domenico Galati, Serena Zanotta, Mariaelena Capone, Gabriele Madonna, Domenico Mallardo, Marilena Romanelli, Ester Simeone, Lucia Festino, Francesca Sparano, Rosa Azzaro, Rosaria De Filippi, Antonello Pinto, Chrystal M Paulos, Paolo Antonio Ascierto
Potential clinical implications of CD4 + CD26 high T cells for nivolumab treated melanoma patients. Journal of translational medicine 21 (1) (2023)
Sara Socorro Faria, Diana Giannarelli, Vladmir Claudio Cordeiro de Lima, Sumadi Luckman Anwar, Chiara Casadei, Ugo De Giorgi, Gabriele Madonna, Paolo Antonio Ascierto, Rossana Verónica Mendoza López, Roger Chammas, Mariaelena Capone
Development of a Prognostic Model for Early Breast Cancer Integrating Neutrophil to Lymphocyte Ratio and Clinical-Pathological Characteristics. The oncologist (2023)
Reinhard Dummer, Philippa Corrie, Ralf Gutzmer, Tarek M Meniawy, Michele Del Vecchio, Celeste Lebbè, Michele Guida, Caroline Dutriaux, Brigitte Dreno, Nicolas Meyer, Pier Francesco Ferrucci, Stéphane Dalle, Muhammad Adnan Khattak, Jean-Jacques Grob, Karen Briscoe, James M G Larkin, Sandrine Mansard, Thierry Lesimple, Massimo Guidoboni, Silvia Sabatini, Erika Richtig, Rudolf Herbst, Maurice Lobo, Margarita Askelson, Paolo Antonio Ascierto, Michele Maio
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Domenico Mallardo, Mario Fordellone, Andrew White, Margaret Ottaviano, Francesca Sparano, Michael D Bailey, Arianna Bianca Facchini, Sufey Ong, Piera Maiolino, Corrado Caracò, Sarah Church, Ernesta Cavalcanti, Sarah Warren, Alfredo Budillon, Alessandra Cesano, Ester Simeone, Paolo Chiodini, Paolo Antonio Ascierto
CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy. Journal of translational medicine 21 (1) (2023)
Susan Costantini, Gabriele Madonna, Elena Di Gennaro, Francesca Capone, Palmina Bagnara, Mariaelena Capone, Silvia Sale, Carmine Nicastro, Lidia Atripaldi, Giuseppe Fiorentino, Roberto Parrella, Vincenzo Montesarchio, Luigi Atripaldi, Paolo Antonio Ascierto, Alfredo Budillon
New Insights into the Identification of Metabolites and Cytokines Predictive of Outcome for Patients with Severe SARS-CoV-2 Infection Showed Similarity with Cancer. International journal of molecular sciences 24 (5) (2023)
James M G Larkin, Michele Del Vecchio, Mario Mandala, Helen J Gogas, Ana M Arance, Stéphane Dalle, Charles Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion Sileni, Ivan Marquez-Rodas, Marcus O Butler, Anna Maria Di Giacomo, Mark Ross Middleton, Jose Lutzky, Luis de la Cruz Merino, Petr Arenberger, Victoria Atkinson, Andrew G Hill, Leslie A Fecher, Michael Millward, Paul D Nathan, Nikhil I Khushalani, Paola Queirolo, Corey Ritchings, Maurice Lobo, Margarita Askelson, Hao Tang, Sonia Dolfi, Paolo Antonio Ascierto, Jeffrey S Weber
Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Domenico Mallardo, Ester Simeone, Lucia Festino, Marilena Tuffanelli, Vito Vanella, Claudia Trojaniello, Maria Grazia Vitale, Margaret Ottaviano, Mariaelena Capone, Gabriele Madonna, Francesca Sparano, Eleonora Cioli, Luigi Scarpato, Marco Palla, Rossella Di Trolio, Paolo Meinardi, Corrado Caracò, Gerardo Ferrara, Paolo Muto, Ernesta Cavalcanti, Paolo Antonio Ascierto
IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab. Journal of translational medicine 21 (1) (2023)
Susan Costantini, Gabriele Madonna, Elena Di Gennaro, Francesca Capone, Palmina Bagnara, Mariaelena Capone, Silvia Sale, Carmine Nicastro, Lidia Atripaldi, Giuseppe Fiorentino, Roberto Parrella, Vincenzo Montesarchio, Luigi Atripaldi, Paolo Antonio Ascierto, Alfredo Budillon
New Insights into the Identification of Metabolites and Cytokines Predictive of Outcome for Patients with Severe SARS-CoV-2 Infection Showed Similarity with Cancer. International journal of molecular sciences 24 (5) (2023)
Joanne M Jeter, Michele Del Vecchio, Jeffrey Weber, Christoph Hoeller, Jean-Jacques Grob, Peter Mohr, Carmen Loquai, Caroline Dutriaux, Vanna Chiarion-Sileni, Jacek Mackiewicz, Piotr Rutkowski, Petr Arenberger, Gaelle Quereux, Tarek M Meniawy, Paolo Antonio Ascierto, Alexander M Menzies, Piyush Durani, Maurice Lobo, Federico Campigotto, Brian Gastman, Georgina V Long
Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nature medicine (2023)
Ignazio Stanganelli, Francesco Spagnolo, Giuseppe Argenziano, Paolo Antonio Ascierto, Franco Bassetto, Paolo Bossi, Vittorio Donato, Daniela Massi, Cesare Massone, Roberto Patuzzo, Giovanni Pellacani, Pietro Quaglino, Paola Queirolo, Iris Zalaudek, Giuseppe Palmieri, null On Behalf Of Italian Melanoma Intergroup Imi
The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts. Cancers 14 (2) (2022)
Igino Simonetti, Piero Trovato, Vincenza Granata, Carmine Picone, Roberta Fusco, Sergio Venanzio Setola, Mauro Mattace Raso, Corrado Caracò, Paolo Antonio Ascierto, Fabio Sandomenico, Antonella Petrillo
Imaging Assessment of Interval Metastasis from Melanoma. Journal of personalized medicine 12 (7) (2022)
Domenico Mallardo, Ester Simeone, Vito Vanella, Maria Grazia Vitale, Marco Palla, Luigi Scarpato, Miriam Paone, Teresa De Cristofaro, Valentina Borzillo, Alessio Cortellini, Francesca Sparano, Sandro Pignata, Francesco Fiore, Corrado Caracò, Piera Maiolino, Antonella Petrillo, Ernesta Cavalcanti, Secondo Lastoria, Paolo Muto, Alfredo Budillon, Sarah Warren, Paolo Antonio Ascierto
Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarization. Journal of translational medicine 20 (1) (2022)
Hussein A Tawbi, Caroline Robert, Jan C Brase, Daniel Gusenleitner, Eduard Gasal, James Garrett, Alexander Savchenko, Güllü Görgün, Keith T Flaherty, Antoni Ribas, Reinhard Dummer, Dirk Schadendorf, Georgina V Long, Paul D Nathan, Paolo Antonio Ascierto
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). Journal for immunotherapy of cancer 10 (6) (2022)
Alexander M Menzies, Ines Pires da Silva, Claudia Trojaniello, Elisabeth Vieu, Rodabe N Amaria, Lisa Zimmer, Serigne N Lo, Elizabeth M Burton, Hussein A Tawbi, Dirk Schadendorf, Jean J Grob, Paolo Antonio Ascierto, Georgina V Long
CTLA-4 Blockade Resistance after Relatlimab and Nivolumab. The New England journal of medicine 386 (17) (2022)
Ines Pires daSilva, Danny Zakria, Tasnia Ahmed, Claudia Trojanello, Florentia Dimitriou, Clara Allayous, Camille Gerard, Lisa Zimmer, Serigne N Lô, Olivier Michielin, Celeste Lebbe, Johanna Mangana, Paolo Antonio Ascierto, Douglas B Johnson, Matteo Carlino, Alexander Menzies, Georgina Long
Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. Journal for immunotherapy of cancer 10 (7) (2022)
Claus Garbe, Ulrike Keim, Teresa Amaral, Carola Berking, Thomas K Eigentler, Lukas Flatz, Anja Gesierich, Ulrike Leiter, Rudolf Stadler, Cord Sunderkoetter, Thomas Tüting, Jochen Utikal, Uwe Wollina, Lisa Zimmer, Christos C Zouboulis, Paolo Antonio Ascierto, Alexander M M Eggermont, Jean-Jacques Grob, Axel Hauschild, Lidija Kandolf Sekulovic, Georgina V Long, Jason John Luke, Olivier Michielin, Ketty Peris, Dirk Schadendorf, Joanne M Jeter, Paul C Lorigan, null null
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (32) (2022)
Hussein A Tawbi, Dirk Schadendorf, Evan J Lipson, Paolo Antonio Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen J Gogas, Christopher D Lao, Juliana Janoski De Menezes, Stéphane Dalle, Ana Arance, Jean-Jacques Grob, Shivani Srivastava, Mena Abaskharoun, Melissa Hamilton, Sarah Keidel, Katy L Simonsen, Anne Marie Sobiesk, Bin Li, F Stephen Hodi, Georgina V Long, null null
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. The New England journal of medicine 386 (1) (2022)
Reinhard Dummer, Keith T Flaherty, Caroline Robert, Ana M Arance, Jan Willem B de Groot, Claus Garbe, Helen J Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liszkay, Carmen Loquai, Mario Mandala, Dirk Schadendorf, Naoya Yamazaki, Alessandra di Pietro, Jean Cantey-Kiser, Michelle Edwards, Paolo Antonio Ascierto
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Paolo Antonio Ascierto, Antonio Avallone, Nina Bhardwaj, Carlo Bifulco, Sergio Bracarda, Joshua D Brody, Luigi Buonaguro, Sandra Demaria, Leisha A Emens, Robert L Ferris, Jérôme Galon, Samir N Khleif, Christopher A Klebanoff, Tamara Laskowski, Ignacio Melero, Chrystal M Paulos, Sandro Pignata, Marco Ruella, Inge Marie Svane, Janis M Taube, Bernard A Fox, Patrick Hwu, Igor Puzanov
Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021. Journal of translational medicine 20 (1) (2022)
Michael B Atkins, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, Michael R Bishop, Daniel C Chen, Madhav Dhodapkar, Leisha A Emens, Marc S Ernstoff, Matthew J Ferris, Tim F Greten, James L Gulley, Roy S Herbst, Rachel W Humphrey, James Larkin, Kim A Margolin, Luca Mazzarella, Suresh S Ramalingam, Meredith M Regan, Brian I Rini, Mario Sznol
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). Journal for immunotherapy of cancer 10 (9) (2022)
Krisztian Homicsko, Reinhard Dummer, Christoph Hoeller, Jedd D Wolchok, F Stephen Hodi, James Larkin, Paolo Antonio Ascierto, Victoria Atkinson, Caroline Robert, Michael A Postow, Sandra Re, David Paulucci, Darin Dobler, Olivier Michielin
Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma. Cancers 14 (9) (2022)
Marco Palla, Luigi Scarpato, Rossella Di Trolio, Paolo Antonio Ascierto
Sonic hedgehog pathway for the treatment of inflammatory diseases: implications and opportunities for future research. Journal for immunotherapy of cancer 10 (6) (2022)
Luigi Fattore, Giordana Cafaro, Marta Di Martile, Virginia Campani, Andrea Sacconi, Domenico Liguoro, Emanuele Marra, Sara Bruschini, Daniela Stoppoloni, Roberto Cirombella, Francesca De Nicola, Matteo Pallocca, Ciro F Ruggiero, Vittorio Castaldo, Angiolina Catizione, Donatella Del Bufalo, Giuseppe Viglietto, Andrea Vecchione, Giovanni Blandino, Luigi Aurisicchio, Maurizio Fanciulli, Paolo Antonio Ascierto, Giuseppe De Rosa, Rita Mancini, Gennaro Ciliberto
Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance. Oncogene (2022)
Jacopo Troisi, Maria Tafuro, Martina Lombardi, Giovanni Scala, Sean M Richards, Steven J K Symes, Paolo Antonio Ascierto, Paolo Delrio, Fabiana Tatangelo, Carlo Buonerba, Bianca Maria Pierri, Pellegrino Cerino
A Metabolomics-Based Screening Proposal for Colorectal Cancer. Metabolites 12 (2) (2022)
Reinhard Dummer, Georgina V Long, Caroline Robert, Hussein A Tawbi, Keith T Flaherty, Paolo Antonio Ascierto, Paul D Nathan, Piotr Lukasz Rutkowski, Oleg Leonov, Caroline Dutriaux, Mario Mandala, Paul C Lorigan, Pier Francesco Ferrucci, Jean-Jacques Grob, Nicolas Meyer, Helen J Gogas, Daniil Stroyakovskiy, Ana M Arance, Jan C Brase, Steven Green, Tomas Haas, Aisha Masood, Eduard Gasal, Antoni Ribas, Dirk Schadendorf
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (13) (2022)
Denis Horgan, Anne-Marie Baird, Mark Ross Middleton, Zhasmina Mihaylova, Jan P Van Meerbeeck, Jens Vogel-Claussen, Paul E Y Van Schil, Josep Malvehy, Paolo Antonio Ascierto, France Dube, Michael Zaiac, Jonathan A Lal, Grażyna Kamińska-Winciorek, Marco Donia, Thierry André, Marta Kozaric, Pia J Osterlund, Dan Lucian Dumitrascu, Lorenzo Spaggiari
How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma? Healthcare (Basel, Switzerland) 10 (9) (2022)
Paolo Antonio Ascierto, Lisa H Butterfield, Olivera J Finn, Andrew Futreal, Omid Hamid, Theresa LaVallee, Michael A Postow, Igor Puzanov, Jeffrey Sosman, Bernard A Fox, Patrick Hwu
The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021. Journal of translational medicine 20 (1) (2022)
Julie R Brahmer, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, Jill Brufsky, Laura C Cappelli, Frank B Cortazar, David E Gerber, Lamya Hamad, Eric Hansen, Douglas B Johnson, Mario E Lacouture, Gregory A Masters, Jarushka Naidoo, Michele Nanni, Miguel-Angel Perales, Igor Puzanov, Bianca D Santomasso, Satish P Shanbhag, Rajeev Sharma, Dimitra Skondra, Jeffrey A Sosman, Michelle Turner, Marc S Ernstoff
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. Journal for immunotherapy of cancer 9 (6) (2022)
Jeffrey S Weber, Mario Mandala, Paolo Antonio Ascierto, James Larkin
Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al . Journal for immunotherapy of cancer 10 (1) (2022)
Jeffrey S Weber, Dirk Schadendorf, Michele Del Vecchio, James M G Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen J Gogas, Stéphane Dalle, Nicolas Meyer, Paolo Antonio Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C Hassel, Caroline Robert, Matteo S Carlino, Anna Maria Di Giacomo, Marcus O Butler, Eva Muñoz Couselo, Michael P Brown, Piotr Lukasz Rutkowski, Andrew M Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis de la Cruz Merino, Andre van der Westhuizen, Alexander M Menzies, Sandra Re, Tuba Bas, Veerle de Pril, Julia Braverman, Daniel J Tenney, Hao Tang, Georgina V Long
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Mario Mandala, James Larkin, Paolo Antonio Ascierto, Michele Del Vecchio, Helen J Gogas, C Lance Cowey, Ana Arance, Stéphane Dalle, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sileni, Ivan Marquez-Rodas, Marcus O Butler, Anna Maria Di Giacomo, Jose Lutzky, Luis De La Cruz-Merino, Victoria Atkinson, Petr Arenberger, Andrew Hill, Leslie Fecher, Michael Millward, Nikhil I Khushalani, Veerle de Pril, Maurice Lobo, Jeffrey S Weber
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. Journal for immunotherapy of cancer 9 (8) (2022)
Paolo Antonio Ascierto, Sanjiv S Agarwala, Christian Blank, Corrado Caracò, Richard D Carvajal, Marc S Ernstoff, Soldano Ferrone, Bernard A Fox, Thomas F Gajewski, Claus Garbe, Jean-Jacques Grob, Omid Hamid, Michelle Krogsgaard, Roger S Lo, Amanda W Lund, Gabriele Madonna, Olivier Michielin, Bart Neyns, Iman Osman, Solange Peters, Poulikos I Poulikakos, Sergio A Quezada, Bradley Reinfeld, Laurence Zitvogel, Igor Puzanov, Magdalena Thurin
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy). Journal of translational medicine 20 (1) (2022)
Domenico Mallardo, Diana Giannarelli, Maria Grazia Vitale, Domenico Galati, Giusy Trillò, Assunta Esposito, Maria Antonietta Isgrò, Grazia D'Angelo, Lucia Festino, Vito Vanella, Claudia Trojaniello, Andrew White, Teresa De Cristofaro, Michael Bailey, Sandro Pignata, Corrado Caracò, Antonella Petrillo, Paolo Muto, Piera Maiolino, Alfredo Budillon, Sarah H Warren, Ernesta Cavalcanti, Paolo Antonio Ascierto
Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis. Journal for immunotherapy of cancer 10 (11) (2022)
Markus W Löffler, Stefania Gori, Francesco Izzo, Andrea Mayer-Mokler, Paolo Antonio Ascierto, Alfred Königsrainer, Yuk Ting Ma, Bruno Sangro, Sven Francque, Luisa Vonghia, Alessandro Inno, Antonio Avallone, Jörg Ludwig, Diego Duarte Alcoba, Christian Flohr, Katrin Aslan, Regina Mendrzyk, Heiko Schuster, Marco Borrelli, Danila Valmori, Tanguy Chaumette, Regina Heidenreich, Cécile Gouttefangeas, Greta Forlani, Maria Tagliamonte, Caterina Fusco, Roberta Penta, Mercedes Iñarrairaegui, Ulrike Gnad-Vogt, Carsten Reinhardt, Toni Weinschenk, Roberto Sergio Accolla, Harpreet Singh-Jasuja, Hans-Georg Rammensee, Luigi Buonaguro
Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (12) (2022)
Francesca Spada, Paolo Bossi, Corrado Caracò, Vanna Chiarion Sileni, Angelo Paolo Dei Tos, Nicola Fazio, Giovanni Grignani, Michele Maio, Pietro Quaglino, Paola Queirolo, Paolo Antonio Ascierto, null null
Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel. Journal for immunotherapy of cancer 10 (6) (2022)

Paolo Antonio Ascierto.css-eqlu8i{font-size:small;padding-left:4px;} (P A Ascierto, Paolo Ascierto, Paolo A Ascierto)

Publication Activity (10 Years)

Top Topics

Top Venues

Paolo Antonio Ascierto (P A Ascierto, Paolo Ascierto, Paolo A Ascierto)